Drug Database
DR

drospirenone (Slinda / LPRICF113 / LF111)

✓ Approved

HyundaiPharm · ESR1 · Steroids

What is drospirenone?

drospirenone is a steroids developed by HyundaiPharm. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesSlinda, LPRICF113, LF111
CompanyHyundaiPharm
Drug ClassSteroids, Small Molecule
Molecular TargetESR1, ESR2, NR3C2, PGR
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, HyundaiPharm

Mechanism of Action

Molecular Targets

drospirenone acts on 4 molecular targets:

ESR1estrogen receptor 1 (ER, ESR)
ESR2estrogen receptor 2 (ESTRB, ER-BETA)
NR3C2nuclear receptor subfamily 3 group C member 2 (NR3C2VIT, MR)
PGRprogesterone receptor (NR3C3, PR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

drospirenone is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Reproductive system and breast disordersDysmenorrhoeaPhase II

Related Research Articles

PubMedInternal medicine journal2026-07-12

Tolerability of hormonal treatments in acute hepatic porphyria patients.

Arandjelovic Andjela A, Ross Charlotte C, Ross Gayle G

Acute hepatic porphyria (AHP) flares have been associated with female hormones and the use of hormonal treatments. Women with AHP are traditionally advised to avoid exogenous oestrogen and progesterone, limiting options for contraception and management of menorrhagia, dysmenorrhoea and menopausal symptoms. Evidence on specific hormonal therapies is limited; a 2003 study found that 25% of women with acute intermittent porphyria (AIP) experienced attacks with contraceptives containing progesterone, oestrogen or both. To update the current understanding of the tolerability of hormonal treatments in women with AHP. An anonymous questionnaire was distributed to women with AHP (acute intermittent porphyria, hereditary coproporphyria and variegate porphyria) via hospital records and a national patient support group, capturing prior hormonal therapy use and associated flares. Thirty responses were analysed; 23 participants had used hormonal therapies. Flares were most frequent in hereditary coproporphyria (66%) and less common in variegate porphyria and acute intermittent porphyria (~20%). No flares were reported with hormone replacement therapy, the progesterone-only pill or progesterone implants. Flares occurred with combined oral contraceptives (46.6%) and progesterone-containing intrauterine devices (28.5%), particularly drospirenone-containing pills. Levonorgestrel-based therapies, including the Mirena IUD, were better tolerated and often improved symptoms. Although limited by sample size and retrospective design, this study provides clinically useful data on the tolerability of specific hormonal therapies in women with AHP, supporting personalised prescribing and patient counselling for contraception and symptom management.

PMID 42435415
Read full article →
PubMedHypertension research : official journal of the Japanese Society of Hypertension2026-07-08

Oral contraceptive-associated hypertension as an under-recognized contributor to secondary and apparent resistant hypertension: agent-specific blood pressure liability, RAAS testing pitfalls, and practical assessment.

Furuto Yoshitaka Y, Yoshino Daiki D, Namikawa Akio A, Sato Dai D et al.

Oral contraceptive-associated hypertension is a long-recognized yet still under-recognized and potentially reversible contributor to elevated blood pressure in women, particularly adolescents and young adults. In Japan, prescribing of low-dose estrogen-progestin preparations has increased; however, available prescription data neither demonstrate an increase in oral contraceptive-associated hypertension nor establish a pill-specific rise in blood pressure among young women. Hormonal exposure may be overlooked because patients may not identify hormonal pills as blood pressure-relevant medicines and because contraceptive prescribing and hypertension assessment often occur in separate clinical settings. Oral contraceptive use may contribute to new-onset hypertension, worsening of established hypertension, apparent resistant hypertension, and misinterpretation of renin-angiotensin-aldosterone system testing. Blood pressure liability varies by formulation: ethinyl estradiol-containing combined hormonal contraceptives warrant the greatest concern, whereas drospirenone-containing or estradiol-based combined pills, progestin-only pills, and implants generally have lower or more neutral blood pressure signals. This review integrates targeted exposure recognition, formulation-specific assessment, home and ambulatory blood pressure monitoring, practical interpretation of a mildly elevated aldosterone-to-renin ratio, and coordinated management of women with new, worsening, or apparent resistant hypertension.

PMID 42414602
Read full article →
PubMedJAMA network open2026-07-02

Contraceptive Progestogens and Incident Meningioma.

Hasselblad Lundstrøm Nicklas N, Hjorslev Knudgaard Mette M, Skaarup Pedersen Michael M, Schougaard Christiansen Marie Louise ML et al.

Meningioma is a known adverse reaction of high-dose progestogens, but evidence regarding the risk associated with progestogens used as contraception is limited. To examine whether different progestogens used as hormonal contraception are associated with increased risk of meningiomas. This nested case-control study conducted over a 25-year study period from January 1, 2000, to December 31, 2024, is a Danish nationwide population-based register study, which included 3 million females aged 15 to 59 years with residence in Denmark. Meningioma cases were dentified, and for each case, 10 controls were matched on age, birthplace, and marital status and randomly selected from the cohort if considered eligible on the day of the case's meningioma diagnosis. Data were analyzed from July 10, 2025, to May 12, 2026. Use of progestogens was identified in the registers by date of dispensing or procedural records and grouped by route of administration and active substance. Exposure time was determined by redeemed daily doses or product duration. If a female switched to a different product or became pregnant, her exposure time was changed to the new exposure. The females included were allocated to their most recent use, defined as the exposure closest to the matching date. The main outcome was incident meningioma and was identified in the Danish National Cancer Register using validated International Statistical Classification of Diseases and Related Health Problems, Tenth Revision diagnoses and International Classification of Diseases for Oncology, Third Edition codes. A total of 1473 cases and 14 717 controls with a median age of 48 years (IQR, 42-53 years) were included in the nested cohort. For combined oral contraceptives, the estimated odds ratios (ORs) for the association between use of progestogens and meningioma were 1.61 (95% CI, 1.00-2.59) with cyproterone, 1.66 (95% CI, 1.31-2.10) with desogestrel, 1.58 (95% CI, 1.05-2.37) with drospirenone, 1.44 (95% CI, 1.17-1.77) with gestodene, 1.40 (95% CI, 1.12-1.76) with levonorgestrel, 1.38 (95% CI, 0.77-2.47) with norethisterone, and 1.04 (95% CI, 0.70-1.54) with norgestimate. For oral progestogen-only contraceptives, the ORs were 1.73 (95% CI, 1.17-2.56) with desogestrel and 0.95 (95% CI, 0.57-1.57) with norethisterone. For injectable medroxyprogesterone, the OR was 4.55 (95% CI, 2.19-9.45). For intrauterine devices (IUDs) with high-dose levonorgestrel, the OR was 1.58 (95% CI, 1.28-1.94), and for IUDs with low-dose levonorgestrel, the OR was 1.14 (95% CI, 0.59-2.22). Exposure within the past year was associated with the highest risk. In this case-control study conducted using data from the entire Danish population, recent use of the contraceptive progestogens cyproterone, desogestrel, drospirenone, gestodene, levonorgestrel, injectable medroxyprogesterone, and high-dose IUD was associated with increased risk of meningioma. These findings are considered relevant information for the treated women and the prescribing physicians.

PMID 42390859
Read full article →
PubMedThe journal of obstetrics and gynaecology research2026-06-09

Cerebral Venous Sinus Thrombosis Occurring During Estetrol/Drospirenone Combined Oral Contraceptive Use in a Woman With Multiple Thrombotic Risk Factors: A Case Report.

Nakahara Mariko M, Fuse Atsuhito A, Ito Yosuke Y, Kasahara Hanako H et al.

Estetrol/drospirenone (E4/DRSP) is a combined oral contraceptive noted for its minimal hemostatic impact compared to ethinyl estradiol-based preparations. However, real-world thrombotic risk data in patients with significant comorbidities remain limited. A woman in her early 40s with adenomyosis and menorrhagia was prescribed E4/DRSP. Six weeks later, she developed acute left upper extremity weakness; imaging confirmed superior sagittal sinus thrombosis. She had severe iron deficiency anemia (hemoglobin 6.4 g/dL). Multiple overlapping risk factors-including severe iron deficiency anemia with reactive thrombocytosis, adenomyosis, obesity, hypertension, and age over 40-likely contributed synergistically, and the independent contribution of E4/DRSP cannot be determined. She was treated with anticoagulation and transitioned to relugolix for adenomyosis management. Although E4/DRSP has a favorable coagulation profile, thrombotic risk persists in women with adenomyosis and severe anemia. Pre-prescription assessment including correction of anemia and consideration of estrogen-free alternatives is warranted.

PMID 42261188
Read full article →
PubMedResearch in social & administrative pharmacy : RSAP2026-05-25

Real-world pharmacovigilance analysis of drug-induced liver injury in 18-65 years: Based on the FDA adverse event reporting system (FAERS).

Wang Xinlong X, Wang Yingying Y, Hu Ting T, Wang Kaijuan K

Drug-induced liver injury (DILI) in adults aged 18-65 years remains understudied despite its clinical heterogeneity and rising incidence. This study aimed to characterize the epidemiology, associated factors, and drug-specific profiles of DILI in this demographic. Utilizing data from the FDA Adverse Event Reporting System (FAERS) (2004-2024), we analyzed 180,659 DILI cases in patients aged 18-65 years. Four disproportionality methods-Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS)-were employed to identify drugs with significant DILI signals. Time-to-onset (TTO) and sex-specific differences were assessed after excluding cases with missing or implausible dates. Twelve drugs exhibited significant DILI signals. Drospirenone; ethinylestradiol (ROR = 16.34, 95%CI: 15.92-16.76), amoxicillin/clavulanic acid (ROR = 6.10, 95%CI: 5.69-6.54), sorafenib (ROR = 5.07, 95%CI: 4.74-5.43), and paracetamol (ROR = 8.76, 95%CI: 8.51-9.01) showed the strongest associations. Analgesics had the shortest median time-to-onset (1 day). Gender subgroup analysis revealed sex-biased hepatotoxicity: 11 drugs met all four criteria in females, with leflunomide (ROR = 4.66, 95%CI: 4.28-5.07) and pembrolizumab (ROR = 4.39, 95%CI: 4.07-4.74) showing strong signals; 14 drugs met the criteria in males, with lamivudine (ROR = 6.87, 95%CI: 6.23-7.58) and amoxicillin/clavulanic acid (ROR = 6.73, 95%CI: 6.08-7.44) among the highest. This analysis identifies antibiotics, immunosuppressants, and hormonal agents as drugs with prominent DILI disproportionality signals in adults aged 18-65 years. The findings advocate for targeted hepatic monitoring and suggest that drug labels could reflect class-specific latency patterns. Sex-specific signal monitoring warrant further investigation.

PMID 42178197
Read full article →
PubMedJournal of thoracic disease2026-05-25

Analysis of drug-induced pulmonary embolism risk based on the Food and Drug Administration Adverse Event Reporting System database.

Rui Yang Y, Xiang Beiyi B, Chen Changwen C, Chen Zhe Z et al.

Drug-induced pulmonary embolism (PE) is a serious adverse drug reaction. While the risk of PE associated with specific medications, such as certain antipsychotics, has been preliminarily investigated, the risks of PE across multiple drug classes in real-world settings are yet to be systematically elucidated. This study utilizes the Food and Drug Administration Adverse Event (AE) Reporting System (FAERS) database, covering data from the first quarter of 2004 to the fourth quarter of 2024, with the objective of identifying drug risk signals that are significantly associated with PE. The findings aim to provide a scientific basis for subsequent clinical medication safety. This study retrieved AE reports related to ''PE'' from the FAERS database and conducted a disproportionality analysis using the reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN). The Preferred Terms (PTs) involved in the study process were standardized using the 27.1 version of the Medical Dictionary for Regulatory Activities (MedDRA). Furthermore, this study systematically classified all drugs involved based on the anatomical therapeutic chemical (ATC) classification standards established by the World Health Organization. This study identified 1,459 drugs associated with the AE of PE, affecting a total of 86,810 patients. Notably, the proportion of female patients was higher than that of male patients. Common drug categories, including antineoplastic and immunomodulating agents, blood and blood-forming organ medications, and nervous system drugs, exhibited strong reporting association signals with PE. The highest number of PE cases was reported for drospirenone/ethinylestradiol, rivaroxaban, and ethinylestradiol/etonogestrel. Through a comprehensive analysis of the FAERS database, this study identified multiple drug categories that exhibit significant positive associations with PE. These findings suggest that clinicians should be vigilant about these potential risk signals, particularly when prescribing long-term treatments to patients with underlying thrombotic risk factors.

PMID 42182709
Read full article →

+1019 more articles available with a free account

Sign up free to view all articles →

Ask about drospirenone